Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,818 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M; CHAMPIONS Study Group. Kinkel RP, et al. Among authors: fox r. Neurology. 2006 Mar 14;66(5):678-84. doi: 10.1212/01.wnl.0000200778.65597.ae. Epub 2006 Jan 25. Neurology. 2006. PMID: 16436649 Clinical Trial.
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC. Plavina T, et al. Among authors: fox r. Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15. Neurology. 2017. PMID: 28916537 Free PMC article. Clinical Trial.
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ. Perumal J, et al. Among authors: fox rj. CNS Drugs. 2023 Mar;37(3):275-289. doi: 10.1007/s40263-022-00982-6. CNS Drugs. 2023. PMID: 36780107 Free PMC article.
Author Correction: Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device.
Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Soltani A, Gazit E, Salis F, Alcock L, Aminian K, Becker C, Bertuletti S, Brown P, Buckley E, Cantu A, Carsin AE, Caruso M, Caulfield B, Cereatti A, Chiari L, D'Ascanio I, Garcia-Aymerich J, Hansen C, Hausdorff JM, Hiden H, Hume E, Keogh A, Kluge F, Koch S, Maetzler W, Megaritis D, Mueller A, Niessen M, Palmerini L, Schwickert L, Scott K, Sharrack B, Sillén H, Singleton D, Vereijken B, Vogiatzis I, Yarnall AJ, Rochester L, Mazzà C, Eskofier BM, Del Din S; Mobilise-D consortium. Kirk C, et al. Sci Rep. 2024 Nov 21;14(1):28878. doi: 10.1038/s41598-024-79454-4. Sci Rep. 2024. PMID: 39572620 Free PMC article. No abstract available.
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.
Danahay H, Gosling M, Fox R, Lilley S, Charlton H, Hargrave JD, Schofield TB, Hay DA, Went N, McMahon P, Marlin F, Scott J, Vile J, Hewison S, Ellam S, Brown S, Sabater J, Kennet G, Lightowler S, Collingwood SP. Danahay H, et al. Among authors: fox r. Eur J Med Chem. 2024 Nov 8;282:117040. doi: 10.1016/j.ejmech.2024.117040. Online ahead of print. Eur J Med Chem. 2024. PMID: 39561495 Free article.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: fox r. Arthritis Rheumatol. 2024 Nov 18. doi: 10.1002/art.43059. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39557617
2,818 results